ELIPS Simulation is developing StroQ, an AI-based software solution that simulates blood flow in the brain on a patient-specific basis, enabling earlier and more individualized detection of strokes. The technology combines clinical imaging, artificial intelligence, and biomechanical simulation to support risk assessments and treatment decisions in real time—especially for patients with vascular constrictions.
The system has been scientifically monitored by Göttingen University Medical Center for several years and is expected to be transferred into clinical routine by 2027. The goal is precise, predictive, and individualized stroke medicine with significant added value for prevention, diagnosis, therapy, and monitoring.
| 2020 | Company founded | |
| 2021 | 2nd place Innovation Award 2022 from the District of Göttingen | |
| 2022 | 2nd place DurchSTARTerpreis "LifeScience" | |
| 10/2025 | Accepted for HTI BioIntelligence Programme |
"Our vision is to establish ELPIS as the leading platform for personalized stroke prevention by translating clinically validated simulation technology into scalable, measurable medical value, thereby setting a new standard for data-driven decision-making in healthcare."
Dr. Artjom Avakian of Allogenetics